ethyl 2-(2-formyl-5-methoxyphenoxy)acetate | 76322-06-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-(2-formyl-5-methoxyphenoxy)acetate
• CAS: 76322-06-0
• 化学式: C₁₂H₁₄O₅
• mdl: MFCD13242461
• 分子量: 238.24
• InChiKey: KNSFGKWYJGYZQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-(2-formyl-5-methoxyphenoxy)acetate 在 盐酸 、 potassium disulphite 、 氢碘酸 、 溶剂黄146 、 tin(ll) chloride 作用下， 反应 9.0h， 生成 (2-羧基甲氧基-4-甲氧基-苯基)-乙酸
  参考文献：
  名称：

  Preparation of synthetic rotenoids(1)

  摘要：

  AbstractSeveral dehydrorotenoids have been prepared by thermal condensation of 4‐ethoxycarbonyl‐3‐chromanon derivatives with 4‐hydroxybenzofurans and 2,2‐dimethyl‐5‐hydroxychroman. Hydrogenation of the dehydrorotenoids in the presence of Pd/BaSO4 afforded rotenoids.

  DOI：

  10.1002/bscb.19800890607
• 作为产物：
  描述：

  2,4-二羟基苯甲醛 在 potassium carbonate 、 potassium iodide 作用下， 以 丙酮 为溶剂， 反应 6.0h， 生成 ethyl 2-(2-formyl-5-methoxyphenoxy)acetate
  参考文献：
  名称：

  Preparation of synthetic rotenoids(1)

  摘要：

  AbstractSeveral dehydrorotenoids have been prepared by thermal condensation of 4‐ethoxycarbonyl‐3‐chromanon derivatives with 4‐hydroxybenzofurans and 2,2‐dimethyl‐5‐hydroxychroman. Hydrogenation of the dehydrorotenoids in the presence of Pd/BaSO4 afforded rotenoids.

  DOI：

  10.1002/bscb.19800890607

文献信息

• Endothelin receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US05686481A1

  公开（公告）日：1997-11-11

  Indole derivatives of formula (1) wherein the substituents are defined herein are disclosed. The compounds are useful in methods of antagonizing endothelin receptors, treating hypertension, treating renal failure and treating cerebrovascular disease. Pharmaceutical compositions are also disclosed.

  公开了式（1）的吲哚衍生物，其中所述的取代基在此处被定义。这些化合物在拮抗内皮素受体、治疗高血压、治疗肾衰竭和治疗脑血管疾病的方法中是有用的。还公开了药物组合物。
• [EN] S1P RECEPTORS MODULATORS AND THEIR USE THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS S1P ET LEUR UTILISATION
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2010043000A1

  公开（公告）日：2010-04-22

  The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

  这项发明涉及具有S1P受体调节活性的新化合物。此外，该发明涉及包括本发明中至少一种化合物的药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，例如自身免疫反应。该发明的另一个方面涉及使用包括本发明中至少一种化合物的药物制造药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，如自身免疫反应。
• Rhodium-Catalyzed Intermolecular Cyclopropanation of Benzofurans, Indoles, and Alkenes via Cyclopropene Ring Opening
  作者：Rachel J. Ross、Rubaishan Jeyaseelan、Mark Lautens

  DOI：10.1021/acs.orglett.0c01655

  日期：2020.6.19

  The generation of metal carbenoids via ring opening of cyclopropenes by transition metals offers a simple entry into highly reactive intermediates. Herein, we describe a diastereoselective intermolecular rhodium-catalyzed cyclopropanation of heterocycles and alkenes using cyclopropenes as carbene precursors with a low loading of a commercially available rhodium catalyst. The reported method is scalable

  通过过渡金属通过环丙烯的开环生成金属类化合物，可轻松进入高反应性中间体。在本文中，我们描述了使用环丙烯作为卡宾前体并以低载量的市售铑催化剂进行非对映选择性分子间铑催化的杂环和烯烃的环丙烷化。所报道的方法是可扩展的，并且可以在低至0.2mol％的催化剂载量下进行，而对反应产率或选择性没有影响。
• [EN] S1P RECEPTORS MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS S1P
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2010042998A1

  公开（公告）日：2010-04-22

  The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

  该发明涉及具有S1P受体调节活性的新化合物，最好具有对癌细胞和其他细胞类型具有凋亡活性和/或抗增殖活性。此外，该发明涉及包含该发明中至少一种化合物的药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，例如癌症。该发明的另一个方面涉及使用包含该发明中至少一种化合物的药物制备药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，如癌症。
• Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site
  作者：Yu-Ying Shao、Yong Yin、Bao-Ping Lian、Jia-Fu Leng、Yuan-Zheng Xia、Ling-Yi Kong

  DOI：10.1016/j.ejmech.2020.112105

  日期：2020.3

  with the IC50 value of 0.18 μM against HT29 cells, which was significantly better than that of the reference drugs shikonin and CA-4. What's more, 6c could inhibit tubulin polymerization and compete with [3H] colchicine in binding to tubulin. Further biological studies depicted that 6c can induce cell apoptosis and cell mitochondria depolarize, regulate the expression of apoptosis related proteins in

  设计并合成了一系列新的紫草素-苯并[b]呋喃衍生物作为微管蛋白聚合抑制剂，并对其生物学活性进行了评估。大多数化合物显示出与紫草素相当的抗癌细胞增殖活性，同时对非癌细胞具有较低的细胞毒性。其中，化合物6c对HT29细胞显示出强大的抗癌活性，IC50值为0.18μM，显着优于参考药物紫草素和CA-4。而且，6c可以抑制微管蛋白聚合，并与[3H]秋水仙碱竞争与微管蛋白的结合。进一步的生物学研究表明6c可以诱导细胞凋亡并使细胞线粒体去极化，调节HT29细胞中凋亡相关蛋白的表达。除了，6c激活了HT29细胞在G2 / M期的细胞周期停滞，并影响了细胞周期相关蛋白的表达。此外，6c显示出对细胞迁移和管形成的有效抑制，这有助于抗血管生成。这些结果促使我们将6c视为潜在的微管蛋白聚合抑制剂，值得进一步研究。